9,684
Total Claims
$3.2M
Drug Cost
1,474
Beneficiaries
$2,170
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+42%
Cost per patient vs peers
$2,170 vs $1,524 avg
Brand vs Generic
100% generic
Brand: 0 claims · $0
Generic: 7,194 claims · $206K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Evolocumab | 742 | $901K |
| Alirocumab | 398 | $498K |
| Empagliflozin | 275 | $398K |
| Semaglutide | 250 | $362K |
| Apixaban | 310 | $340K |
| Tirzepatide | 104 | $131K |
| Rivaroxaban | 98 | $115K |
| Sacubitril/Valsartan | 39 | $54K |
| Dapagliflozin Propanediol | 46 | $46K |
| Ezetimibe | 985 | $41K |
| Evolocumab | 31 | $34K |
| Pitavastatin Calcium | 47 | $28K |
| Olmesartan Medoxomil | 450 | $15K |
| Icosapent Ethyl | 14 | $15K |
| Rosuvastatin Calcium | 777 | $13K |
Prescribing Profile
Patient Profile
75
Avg Age
46%
Female
1.14
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data